For example, high-dose (HD) IL-2 cancer immunotherapy stimulates the proliferation of cytotoxic CD8+ T-cells and NK cells, promoting tumor regression24,25, and it has been approved for the treatment of metastatic melanoma and renal cancer for its anti-tumor activity26,27. The gene discussed is CD8A; the disease is cancer.